Skip to main content

Currently Skimming:

6 A Blueprint for Action
Pages 119-130

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 119...
... During its deliberations, the committee explored a range of topics that it decided to categorize in the dimensions of basic and translational science, clinical science, manufacturing science, and regulatory science. The recommendations presented in this chapter can serve collectively as a blueprint for action to accelerate the vaccine development process, increase access to vaccines, and limit global vaccine inequity.
From page 120...
... A priority need, then, is for the allocation of a continuous and permanent stream of funding to support the development of broadly protective influenza vaccines, as well as novel vaccine platform technologies. For pandemic preparedness, the additional development of vaccines targeting conserved epitopes, or other types of broadly protective vaccine constructs, such as supraseasonal, pan-subtype, or pan-group, is vital to developing a pandemic-ready stockpile.
From page 121...
... Financial aid could stimulate vaccine manufacturers to take a risk-based approach to pandemic influenza preparedness, understanding that the investments made would be a form of insurance that would limit the costs of the next impending influenza outbreak. To qualify for these funding initiatives, manufacturers would be required to participate in R&D, data sharing, technology adaptation, and training activities with international partners.
From page 122...
... Organizations and governments can help meet this need by supporting and encouraging vaccine manufacturers to prioritize and harmonize influenza vaccine development and manufacturing capacity. The approach taken by the Coalition for Epidemic Preparedness Innovations (CEPI)
From page 123...
... Likewise, regulators need to develop clear pathways for the development of new vaccine platforms for seasonal influenza that are designed to generate data on multiple correlates of protection, efficacy, and safety. Given the crucial importance of data sharing between industry and regulators, regulators also need to develop protocols for these processes, as well as for chemistry, manufacturing, and control process inspections.
From page 124...
... The COVID-19 pandemic showed the importance of clear and transparent public communications for vaccine acceptance in populations. Reduced trust and credibility among the public were the result of multiple factors, including a lack of transparency in the dissemination of data regarding the safety and risk of various vaccine candidates and results of risk–benefit analyses, along with the politicization of vaccine development.
From page 125...
... This disadvantage should be addressed in developing a sustainable model for addressing future outbreaks. An optimal harmonized framework for clinical development of vaccines for influenza would require coordinated funding for clinical trials that include diverse populations and are distributed globally.
From page 126...
... Department of Defense, as well as other corresponding governmental and funding agencies domestically and abroad, should invest, proportionate to the enormous costs of pandemics, in basic and translational research to reveal a diverse array of influenza vaccines, using different platforms, viral targets, adjuvants, and delivery systems. This will allow selection of the candidates most fit for purpose to be brought to authorization and sufficient production and distribution to optimize the control of influenza across diverse settings and phases of pandemics and epidemics.
From page 127...
... Centers for Disease Control and Pre vention funding networks) supported by governments and funding agencies, the World Health Organization, and the vaccine industry should support, carefully plan, and conduct multi-center international clinical trials and field studies to compare emerging vaccines with stan dard vaccines in, among others, geographically, demographically, and immunologically diverse populations to inform rational and situation based use and manufacture of an extended array of vaccines.
From page 128...
... This includes • Convening, supporting, and encouraging multi-national, public, and private vaccine manufacturers to benchmark, prioritize, and harmonize influenza vaccine manufacturing; and • Enhancing and expanding support of the global influenza vac cine manufacturing network, creating manufacturing hubs for greater collaboration, and building capacity to address chal lenges in manufacturing in low- and middle-income countries. Recommendation 4-2: Vaccine manufacturers should take a risk-based approach to pandemic influenza preparedness.
From page 129...
... Food and Drug Administration and other national regulators (e.g., European Medicines Agency) should commit to transparency in the oversight of clinical trials, review of data, authorization, and approval of pandemic influenza vaccines, in cluding the release of facility inspection findings, clinical trial protocols, and clinical data that are the basis of decision making.
From page 130...
... 2021. Global production capacity of seasonal and pandemic influenza vaccines in 2019.


This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More information on Chapter Skim is available.